Automatic region-of-interest segmentation and registration of dynamic contrast-enhanced images of colorectal tumors

Dynamic contrast-enhanced (DCE) images can be acquired at multiple time points and multiple slice locations of a tumor. Image segmentation and registration are important preprocessing steps that can improve subsequent analysis of DCE images by kinetic modeling. An automatic system for region-of-interest segmentation and registration of DCE images is presented. Tissue segmentation is performed using a combination of thresholding and morphological operations, and further refined using shape information from consecutive images. The segmented regions are subsequently registered based on a mutual information method that accounts for possible tissue movement between slices. The proposed segmentation and registration methods are applied on actual DCE CT datasets to illustrate feasibility of practical implementation in the clinic.

Molecular imaging to predict ventricular arrhythmia in heart failure

Ventricular tachycardia (VT) is a major cause of sudden cardiac death (SCD) in patients with heart failure (HF). Left ventricular ejection fraction (LVEF) and heart failure class according to the New York Heart association (NYHA) are in most common use to identify patients that may benefit from implantable cardioverter defibrillator (ICD) therapy. But during 3 years of follow up only 35% of patients receive appropriate ICD action. Therefore, there is a continued need for refinement of selection criteria for ICD implantation. In this regard, molecular imaging of the autonomic nervous system, which plays a central role in HF progression and cardiac electro-mechanical regulation, can make a substantial contribution. This article reviews the currently available literature concerning the value of molecular neuronal cardiac imaging for prediction of ventricular arrhythmias in HF patients.

Molecular imaging of plaque vulnerability

Over the past decade, significant progress has been made in the development of novel imaging strategies focusing on the biology of the vessel wall for identification of vulnerable plaques. While the majority of these studies are still in the pre-clinical stage, few techniques (e.g., (18)F-FDG and (18)F-NaF PET imaging) have already been evaluated in clinical studies with promising results. Here, we will briefly review the pathobiology of atherosclerosis and discuss molecular imaging strategies that have been developed to target these events, with an emphasis on mechanisms that are associated with atherosclerotic plaque vulnerability.

Uptake of aortic 18F-FDG is correlated with low-density lipoprotein cholesterol and leptin in a general population

Objective

This study investigated the relationship between aortic ¹⁸F-fluoro-2-deoxy-D-glucose (¹⁸F-FDG) uptake and clinical and laboratory findings related to atherosclerosis in a general population.

Methods

¹⁸F-FDG uptake in the ascending aorta was measured on the positron emission tomography/computed tomography (PET/CT) scans of 211 Japanese adults. The maximum target-to-background ratio (TBR) was compared with clinical and laboratory atherosclerosis findings.

Results

By multivariate regression analysis adjusted for age and sex, TBR-ascending aorta (TBR-A) was significantly correlated with various clinical and laboratory parameters, such as body mass index, log visceral fat area, low-density lipoprotein cholesterol (LDL-C), log fasting immunoreactive insulin, log homeostasis model assessment of insulin resistance, log total adiponectin and log-leptin, in all subjects. Furthermore, by multivariate linear regression analysis adjusted for confounding factors, TBR-A was significantly correlated with LDL-C (β = 0.001, p = 0.03) and log-leptin (β = 0.336, p<0.01) in all subjects.

Conclusion

TBR-A was significantly correlated with LDL-C and log-leptin independent from confounding factors. Our results suggest that aortic ¹⁸F-FDG uptake is a good marker of atherosclerosis, even in a general population.

Alternating direction method of multiplier for tomography with nonlocal regularizers

The ordered subset expectation maximization (OSEM) algorithm approximates the gradient of a likelihood function using a subset of projections instead of using all projections so that fast image reconstruction is possible for emission and transmission tomography such as SPECT, PET, and CT. However, OSEM does not significantly accelerate reconstruction with computationally expensive regularizers such as patch-based nonlocal (NL) regularizers, because the regularizer gradient is evaluated for every subset. We propose to use variable splitting to separate the likelihood term and the regularizer term for penalized emission tomographic image reconstruction problem and to optimize it using the alternating direction method of multiplier (ADMM). We also propose a fast algorithm to optimize the ADMM parameter based on convergence rate analysis. This new scheme enables more sub-iterations related to the likelihood term. We evaluated our ADMM for 3-D SPECT image reconstruction with a patch-based NL regularizer that uses the Fair potential function. Our proposed ADMM improved the speed of convergence substantially compared to other existing methods such as gradient descent, EM, and OSEM using De Pierro's approach, and the limited-memory Broyden-Fletcher-Goldfarb-Shanno algorithm.

Nuclear imaging to support anti-inflammatory drug discovery and development

Nuclear medicine contributes important tools to support anti-inflammatory drug discovery and development. The support provided is manifold: new molecular entities (NME, either small molecules or biologics) labeled with radioisotopes can be applied in animal models and humans to measure biodistribution, target engagement, and pharmacokinetics. In addition, nuclear imaging techniques can be used to select or enrich the patient populations in clinical trials, to assess disease activity, target status and distribution and to quantify response to therapeutic interventions. In the first part of this review we will outline how nuclear imaging techniques can be applied to support informed decision making in drug development. In the second part, we will briefly high-light the use of nuclear imaging of inflammation in drug development in selected diseases, specifically rheumatoid arthritis (RA), inflammatory bowel diseases (IBD), atherosclerosis and - as an emerging topic - cancer.

Imaging T-lymphocytes in inflammatory diseases: a nuclear medicine approach

Increasing interest and research efforts have been made in search of specific radiolabelled probes for imaging different immune cells (including T-lymphocytes) in inflammation and infection. This has led to early detection of lymphocyte infiltration, and the deepening of our understanding of pathogenesis of immune mediated diseases. In-vivo imaging of T-lymphocytes with radiolabelled specific probes may provide an important piece of information about inflammatory lesions, which could be very important to understand the molecular mechanism of action of any drug and/or their effect on the microenvironment of the immune system of the body. The present review focuses on radiolabelled T-lymphocytes and different monoclonal antibodies, peptides, cytokines, chemokine used for scintigraphic imaging of T-lymphocytes and their subsets.

NK cell imaging by in vitro and in vivo labelling approaches

Natural killer (NK) cells are a particular lymphocyte subset with a documented cytotoxic activity against cancer cells. Evidence of NK antitumoral effect led researchers to focus on the development of immunotherapies aimed at augmenting NK recruitment and infiltration into tumor and their anti-cancer functions. Studies in animal models proved that the right combination of drugs, cytokines, chemokines and other factors might be used to enhance or suppress tumor targeting by NK cells. Therefore, it would be necessary to have a tool to non-invasively monitor the efficacy of such novel therapies. Available imaging techniques comprise magnetic resonance, optical and nuclear medicine imaging with a pool of compounds that ranges from radiolabelled nanoparticles and radiopharmaceuticals to fluorescent probes. Each tracer and technique has its own pros and cons, but till now, no one emerged as superior among the others.

Imaging B lymphocytes in autoimmune inflammatory diseases

B cells arise from stem cells precursor and develop through a tightly regulated and selective process that lead to the generation of different B cell populations such as transitional, mature, memory and plasma cells. These B cell subsets can be identified using flow cytometry by the expression of specific surface antigens. The growing knowledge of the pivotal role played by B cells in the development and progression of autoimmune diseases combined with the advances in monoclonal antibody technology, led in the last years to the generation of different biological agents targeting B cells. In this context, nuclear medicine can offer the possibility to use a panel of biologic radiopharmaceuticals for molecular imaging of inflammatory diseases. Radiopharmaceuticals bind to their targets with high affinity and specificity and have an excellent imaging diagnostic potential for the evaluation of disease activity, selection and monitoring of immune therapies. Several molecules have been radiolabelled for the imaging of T lymphocytes whereas, by now, the anti CD20 rituximab is the only biological therapy targeting B cells that demonstrated to be efficiently radiolabelled and used to detect inflammation in autoimmune patients.

Targeting monocytes and macrophages by means of SPECT and PET

Monocytes have been isolated from patient's blood and directly radiolabelled in vitro using a variety of radiopharmaceuticals such as 99mTc-HMPAO, 111In-oxine, 99mTc-colloids and 18F-FDG. Overall, the best labeling results were obtained using 99mTc-HMPAO. The wide availability of 99mTc and of the ligand HMPAO in kit-formulation makes it the most versatile procedure for imaging localized inflammation using in-vitro labeling. Injection of 99mTc-HMPAO labeled monocytes in adult patients has proven safe with an effective dose of 0.011 mSv/Mbq, equivalent to that of 99mTc-HMPAO labeled mixed white blood cells. Furthermore, in a proof of concept studies, in-vitro labeled monocytes were shown to specifically accumulate in the bowels of patients suffering from inflammatory bowel disease as well as in inflamed joints of rheumatoid arthritis patients. Inversely, the decrease in disease activity of inflamed joints of rheumatoid arthritis patients treated by Adalimumab could not be substantiated using 99mTc-HMPAO labelled monocytes suggesting this type of treatment does not reduce monocyte influx. In spite of their wide availability, in-vitro labeling procedures are cumbersome and time-consuming. Furthermore, cell activation may occur during the labeling process and it cannot be excluded that the radiopharmaceuticals used for labelling interfere with ongoing cellular processes. As such, various authors turned towards the development of radiopharmaceuticals for in-vivo labeling of both monocytes and more importantly macrophages, many of which were subsequently validated in animal models. Targets studied in this regard include amongst others the folate receptor, the mannose receptor, the peripheral benzodiazepine receptor as well as more general characteristics of macrophages such as phagocytosis. Various of these novel molecules appear promising and clinical studies using these radiopharmaceuticals are awaited in the near future. Some of these radiopharmaceuticals also reached the clinical stage, respectively the translocating protein targeting radiopharmaceutical 11C-PK11195 and the folate receptor targeting radiopharmaceutical 99mTc-EC20. Uptake of 11C-PK11195 in inflamed joints and sites of atherosclerosis in patients proved to be directly related to the number of peripheral benzodiazepine binding receptors available as well as to the severity of ongoing inflammation. Comparable results were obtained using 99mTc-EC20 in rheumatoid arthritis patients. In spite of these promising results, additional studies are warranted demonstrating that in vivo, quantitative visualization of monocyte trafficking and accumulation of M1 or M2 macrophage subtypes in sites of ongoing inflammation by means of SPECT and PET will contribute to a better understanding of human inflammatory diseases as well as to diagnosis, treatment planning and the development of targeted treatment strategies.

Role of isotope scan, including positron emission tomography/computed tomography, in nodular goitre

Nuclear medicine techniques were first used in clinical practice for diagnosing and treating thyroid diseases in the 1950s, and are still an integral part of thyroid nodules work-up. Thyroid imaging with iodine or iodine-analogue isotopes is the only examination able to prove the presence of autonomously functioning thyroid tissue, which excludes malignancy with a high probability. In addition, a thyroid scan with technetium-99m-methoxyisobutylisonitrile is able to avoid unnecessary surgical procedures for cytologically inconclusive thyroid nodules, as confirmed by meta-analysis and cost-effectiveness studies. Finally, positron emission tomography alone, and positron emission tomography combined with computed tomography scans with (18)F-fluoro-2-deoxy-d-glucose are also promising for diagnosing thyroid diseases, but further studies are needed before introducing them to clinical practice.

[Prognostic value of 18F-FDG positron emission tomography in the early evaluation of the efficiency of treatment in patients with non-Hodgkin lymphomas]

OBJECTIVE

To define the role of 18F-FDG positron emission tomography (PET) performed after 2-3 chemotherapy cycles in the prediction of disease prognosis and to identify a group of patients requiring more intensive treatment.

MATERIAL AND METHODS

Seventy-one patients with non-Hodgkin lymphoma of different histological types were examined. PET was carried out at different stages of diagnosis and primary treatment in the patients.

RESULTS

The examinations made after 2-3 polychemotherapy (PCT) cycles indicated that 36 (50.7%) patients continued to have signs of metabolic activity of lymphoproliferative disease (a PET-positive group) and 35 (49.3%) patients were found to have no abnormal tracer accumulation foci (a PET-negative group). Twenty-nine (82.9%) patients from the PET-negative group continued to remain in complete remission throughout the follow-up (the median follow-up was 405 days). At late stages, 6 (17.1%) patients were identified to have abnormal tracer hyperfixation foci that were indicative of disease recurrence. Only 8 patients from the PET-positive group were observed to show a complete metabolic response to treatment at the end of first-line PCT. The metabolic activity of the disease was maintained in the remaining patients. The results of PET conducted at the late stages of the follow-up indicated that metabolically active tumor foci continued to be visualized in 20 (55.6%) patients and further treatment resulted in complete remission in 16 (44.4%) patients.

CONCLUSION

PET findings could predict the further course of the disease and differentiate more intensive treatment-requiring patients at the early stages of chemotherapy.

Low-activity (124)I-PET/low-dose CT versus (131)I probe measurements in pretherapy assessment of radioiodine uptake in benign thyroid diseases

CONTEXT

Radioiodine therapy of benign thyroid diseases requires pretherapy assessment of radioactive iodine uptake (RAIU) for reliable therapy planning.

OBJECTIVE

Our objective was to assess RAIU by low-activity (124)I-positron emission tomography/low-dose computed tomography ((124)I-PET/CT) in comparison with standard (131)I probe measurements.

DESIGN/SETTING

This prospective comparative study was conducted at the Jena University Hospital, Jena, Germany, in a referral center setting.

PATIENTS

A total of 79 patients with benign thyroid diseases were screened, 40 of whom met the inclusion criteria (stable TSH, free T3 and free T4 levels; no thyroid-specific medication, no iodine contamination) and 24 of whom agreed to participate by signing an informed consent.

INTERVENTIONS

All patients received the standard (131)I scintillation probe uptake test 30 hours after administration of 3 MBq (131)I. Seven days later, all patients were subjected to (124)I-PET/CT uptake measurement 30 hours after administration of 1 MBq (124)I.

MAIN OUTCOME MEASURES

The decay-corrected uptake values of both techniques were compared. Additionally, 3 different volume-of-interest-based evaluation methods in PET/CT (whole neck [WN], automatic isocontour [IC], and manually contoured [MC]) were evaluated.

RESULTS

The (131)I probe measurement and (124)I-PET.WN method provided very similar mean RAIU (30.7% ± 10.3%; 31.7% ± 8.9%), resulting in a significant positive correlation (r = 0.93, P < .001). Compared with (124)I-PET.WN, the (124)I-PET.IC (29.8% ± 8.6%) and the (124)I-PET.MC (24.5% ± 7.1%) demonstrated lower uptake values.

CONCLUSIONS

Using activities as low as 1 MBq, the (124)I-PET.WN method shows a good correlation with conventional (131)I probe measurement. Thus, (124)I-PET/CT is a suitable alternative for pretherapy RAIU evaluations. This may offer potential additional benefits such as PET/ultrasound fusion imaging and CT volumetry.

Clinical decision support systems in myocardial perfusion imaging

Diagnostic imaging is becoming more complicated, physicians are also required to master an ever-expanding knowledge base and take into account an ever increasing amount of patient-specific clinical information while the time available to master this knowledge base, assemble the relevant clinical data, and apply it to specific tasks is steadily shrinking. Compounding these problems, there is an ever increasing number of aging "Baby Boomers" who are becoming patients coupled with a declining number of cardiac diagnosticians experienced in interpreting these studies. Hence, it is crucial that decision support tools be developed and implemented to assist physicians in interpreting studies at a faster rate and at the highest level of up-to-date expertise. Such tools will minimize subjectivity and intra- and inter-observer variation in image interpretation, help achieve a standardized high level of performance, and reduce healthcare costs. Presently, there are many decision support systems and approaches being developed and implemented to provide greater automation and to further objectify and standardize analysis, display, integration, interpretation, and reporting of myocardial perfusion SPECT and PET studies. This review focuses on these systems and approaches.

[Difficulties in the radiodiagnosis of lung injuries in phthisiatric practice]

The paper describes clinical cases of concomitant lung and intrathoracic lymph node involvements as evidenced by conventional radiography and computed tomography (CT). It shows difficulties in the differential diagnosis of different nosological entities in pulmonary tuberculosis. The x-ray semiotics of concomitant lung injuries is also depicted.

Simulations of breast cancer imaging using gamma-ray stimulated emission computed tomography

Here, we present an innovative imaging technology for breast cancer using gamma-ray stimulated spectroscopy based on the nuclear resonance fluorescence (NRF) technique. In NRF, a nucleus of a given isotope selectively absorbs gamma rays with energy exactly equal to one of its quantized energy states, emitting an outgoing gamma ray with energy nearly identical to that of the incident gamma ray. Due to its application of NRF, gamma-ray stimulated spectroscopy is sensitive to trace element concentration changes, which are suspected to occur at early stages of breast cancer, and therefore can be potentially used to noninvasively detect and diagnose cancer in its early stages. Using Monte-Carlo simulations, we have designed and demonstrated an imaging system that uses gamma-ray stimulated spectroscopy for visualizing breast cancer. We show that gamma-ray stimulated spectroscopy is able to visualize breast cancer lesions based primarily on the differences in the concentrations of trace elements between diseased and healthy tissue, rather than differences in density that are crucial for X-ray mammography. The technique shows potential for early breast cancer detection; however, improvements are needed in gamma-ray laser technology for the technique to become a clinically feasible method of detecting and diagnosing cancer at early stages.

In vivo measurement of hippocampal GABAA/cBZR density with [18F]-flumazenil PET for the study of disease progression in an animal model of temporal lobe epilepsy

Purpose

Imbalance of inhibitory GABAergic neurotransmission has been proposed to play a role in the pathogenesis of temporal lobe epilepsy (TLE). This study aimed to investigate whether [¹⁸F]-flumazenil ([¹⁸F]-FMZ) PET could be used to non-invasively characterise GABA_A/central benzodiazepine receptor (GABA_A/cBZR) density and affinity in vivo in the post-kainic acid status epilepticus (SE) model of TLE.

Methods

Dynamic [¹⁸F]-FMZ -PET scans using a multi-injection protocol were acquired in four male wistar rats for validation of the partial saturation model (PSM). SE was induced in eight male Wistar rats (10 weeks of age) by i.p. injection of kainic acid (7.5–25 mg/kg), while control rats (n = 7) received saline injections. Five weeks post-SE, an anatomic MRI scan was acquired and the following week an [¹⁸F]-FMZ PET scan (3.6–4.6 nmol). The PET data was co-registered to the MRI and regions of interest drawn on the MRI for selected structures. A PSM was used to derive receptor density and apparent affinity from the [¹⁸F]-FMZ PET data.

Key Findings

The PSM was found to adequately model [¹⁸F]-FMZ binding in vivo. There was a significant decrease in hippocampal receptor density in the SE group (p<0.01), accompanied by an increase in apparent affinity (p<0.05) compared to controls. No change in cortical receptor binding was observed. Hippocampal volume reduction and cell loss was only seen in a subset of animals. Histological assessment of hippocampal cell loss was significantly correlated with hippocampal volume measured by MRI (p<0.05), but did not correlate with [¹⁸F]-FMZ binding.

Significance

Alterations to hippocampal GABA_A/cBZR density and affinity in the post-kainic acid SE model of TLE are detectable in vivo with [¹⁸F]-FMZ PET and a PSM. These changes are independent from hippocampal cell and volume loss. [¹⁸F]-FMZ PET is useful for investigating the role that changes GABA_A/cBZR density and binding affinity play in the pathogenesis of TLE.

Evaluation of imaging systems using the posterior variance of emission counts

We investigate an approach to evaluation of emission-tomography (ET) imaging systems used for region-of-interest (ROI) estimation tasks. In the evaluation we employ the concept of "emission counts" (EC), which are the number of events per voxel emitted during a scan. We use the reduction in posterior variance of ROI EC, compared to the prior ROI EC variance, as the metric of primary interest, which we call the "posterior variance reduction index" (PVRI). Systems that achieve a higher PVRI are considered superior to systems with lower PVRI. The approach is independent of the reconstruction method and is applicable to all photon-limited data types including list-mode data. We analyzed this approach using a model of 2-D tomography, and compared our results to the classical theory of tomographic sampling. We found that performance evaluations using the PVRI index were consistent with the classical theory. System evaluation based on EC posterior variance is an intuitively appealing and physically meaningful method that is useful for evaluation of system performance in ROI quantitation tasks.

Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study

BACKGROUND

Small benign insulinomas are hard to localise, leading to difficulties in planning of surgical interventions. We aimed to prospectively assess the insulinoma detection rate of single-photon emission CT in combination with CT (SPECT/CT) with a glucagon-like peptide-1 receptor avid radiotracer, and compare detection rates with conventional CT/MRI techniques.

METHODS

In our prospective imaging study, we enrolled adults aged 25-81 years at centres in Germany, Switzerland, and the UK. Eligible patients had proven clinical and biochemical endogenous hyperinsulinaemic hypoglycaemia and no evidence for metastatic disease on conventional imaging. CT/MRI imaging was done at referring centres according to standard protocols. At three tertiary nuclear medicine centres, we used whole body planar images and SPECT/CT of the abdomen up to 168 h after injection of (111)In-[Lys40(Ahx-DTPA-(111)In)NH2]-exendin-4 ((111)In-DTPA-exendin-4) to identify insulinomas. Consenting patients underwent surgery and imaging findings were confirmed histologically.

FINDINGS

Between Oct 1, 2008, and Dec 31, 2011, we recruited 30 patients. All patients underwent (111)In-DTPA-exendin-4 imaging, 25 patients underwent surgery (with histological analysis), and 27 patients were assessed with CT/MRI. (111)In-DTPA-exendin-4 SPECT/CT correctly detected 19 insulinomas and four additional positive lesions (two islet-cell hyperplasia and two uncharacterised lesions) resulting in a positive predictive value of 83% (95% CI 62-94). One true negative (islet-cell hyperplasia) and one false negative (malignant insulinoma) result was identified in separate patients by (111)In-DTPA-exendin-4 SPECT/CT. Seven patients (23%) were referred to surgery on the basis of (111)In-DTPA-exendin-4 imaging alone. For 23 assessable patients, (111)In-DTPA-exendin-4 SPECT/CT had a higher sensitivity (95% [95% CI 74-100]) than did CT/MRI (47% [27-68]; p=0.011).

INTERPRETATION

(111)In-DTPA-exendin-4 SPECT/CT could provide a good second-line imaging strategy for patients with negative results on initial imaging with CT/MRI.

FUNDING

Oncosuisse, the Swiss National Science Foundation, and UK Department of Health.

Fundamentals of Positron Emission Tomography and Applications in Preclinical Drug Development

Positron emission tomography (PET) is a nuclear imaging technique that can dynamically image trace amounts of positron-labeled radiopharmaceuticals in vivo. Tracer concentrations can be determined quantitatively, and by application of appropriate tracer kinetic models, the rates of a wide range of different biological processes can be measured noninvasively in humans. PET has been used as a research tool for more than 25 years and has also found clinical applications, particularly in oncology, neurological disorders, and cardiovascular disease. Recently, there has been tremendous interest in applying PET technology to in vivo small-animal imaging. Significant improvements in the imaging technology now permit a wide range of PET studies in mice and rats, using compact, relatively low-cost, dedicated small-animal PET scanners. This article reviews the fundamental basis of PET imaging and discusses the development of small-animal PET scanners and their possible application in preclinical drug development.

The evolution in the use of MIBG scintigraphy in pheochromocytomas and paragangliomas

Radioiodinated metaiodobenzylguanidine (MIBG) was developed in the late 1970's, at the Michigan University Medical Center, for imaging of the adrenal medulla and its diseases. Soon after, MIBG was shown to depict a wide range of tumors of neural crest origin other than pheochromocytomas/paragangliomas (Pheo/PGL) with the result that its use rapidly spread to many countries. After more than 30 years of clinical application, MIBG continues to be the most widespread radiopharmaceutical for the functional imaging of Pheo/PGL in spite of the emergent role of PET agents for detection of these tumors. In this paper we review the evolution in the use of MIBG over more than 30 years of experimental and clinical applications, with particular focus on the uptake mechanisms, pharmacokinetics, biodistribution and drug interaction as well as on clinical studies in Pheo/PGL also in comparison to other gamma-emitters tracers and PET radiopharmaceuticals.

Imaging approaches for dementia

Brain imaging has progressed from exclusion of rare treatable mass lesions to a specific antemortem diagnosis. MR imaging-derived hippocampal atrophy and WMH are regarded as imaging biomarkers of AD and CVD respectively. Abnormal FP-CIT SPECT or cardiac iodobenzamide SPECT is a useful supportive imaging feature in the diagnosis of DLB. Frontal and/or anterior temporal atrophy and anterior defects on molecular imaging with FDG-PET or perfusion SPECT are characteristic of FTDs. Whole-body FDG-PET may be helpful in patients with rapidly progressing "autoimmune dementias," and FLAIR and DWI are indicated in suspected CJD. A major role of imaging is in the development of new drugs and less costly biomarkers.

Generalized EM-type reconstruction algorithms for emission tomography

We provide a general form for many reconstruction estimators of emission tomography. These estimators include Shepp and Vardi's maximum likelihood (ML) estimator, the quadratic weighted least squares (WLS) estimator, Anderson's WLS estimator, and Liu and Wang's multi-objective estimator, and others. We derive a generic update rule by constructing a surrogate function. This work is inspired by the ML-EM (EM, expectation maximization), where the latter naturally arises as a special case. A regularization with a specific form can also be incorporated by De Pierro's trick. We provide a general and quite different convergence proof compared with the proofs of the ML-EM and De Pierro. Theoretical analysis shows that the proposed algorithm monotonically decreases the cost function and automatically meets nonnegativity constraints. We have introduced a mechanism to provide monotonic, self-constraining, and convergent algorithms, from which some interesting existing and new algorithms can be derived. Simulation results illustrate the behavior of these algorithms in term of image quality and resolution-noise tradeoff.

Role of cardiac imaging in heart failure

Heart failure is the leading cause of mortality and rehospitalization in Western countries. With the development of new technologies applied to medical diagnostic pathways, cardiovascular imaging has rapidly gained ground. Therefore, the clinical cardiologist has to keep updated on the management of such innovative diagnostic tools which were once the exclusive domain of radiologists. The need to understand a new language is fundamental for the selection of diagnostic and therapeutic strategies in patients with heart failure, which is often the final destination for many cardiovascular diseases. Alongside standard diagnostic techniques such as chest radiography two-dimensional ultrasound and cardiac color Doppler, all of which are indispensable in daily practice, innovative tools have been defining their incremental role in cardiovascular imaging. Cardiac magnetic resonance (CMR), cardiac computed tomography (CT), speckle tracking, 3D echocardiography, new applications in nuclear medicine (SPECT MIBG), and "cardiac hybrid imaging" are emerging for research and are also playing a pivotal role in the clinical scenario. These techniques are useful the for non-invasive acquisition of diagnostic and prognostic information in heart failure. Whether the radiological and economic impact of these new technologies is sustainable is a question the clinical cardiologist will need to answer when considering the cost/benefit of the diagnostic tool selected among these methods.

Quantitative assessment of lesion detection accuracy, resolution, and reconstruction algorithms in neutron stimulated emission computed tomography

We present a quantitative analysis of the image quality obtained using filtered back-projection (FBP) with Ram-Lak filtering and maximum likelihood-expectation maximization (ML-EM)-with no post-reconstruction filtering in either case-in neutron stimulated emission computed tomography (NSECT) imaging using Monte Carlo simulations in the context of clinically relevant models of liver iron overload. The ratios of pixel intensities for several regions of interest and lesion shape detection using an active-contours segmentation algorithm are assessed for accuracy across different scanning configurations and reconstruction algorithms. The modulation transfer functions (MTFs) are also computed for the cases under study and are applied to determine a minimum detectable lesion spacing as a form of sensitivity analysis. The accuracy of NSECT imaging in measuring relative tissue concentration is presented for simulated clinical liver cases. When using the 15th iteration, ML-EM provides at least 25% better resolution than FBP and proves to be highly robust under low-signal high-noise conditions prevalent in NSECT. However, FBP gives more accurate lesion pixel intensity ratios and size estimates in some cases; due to advantages provided by both reconstruction algorithms, it is worth exploring the development of an algorithm that is a hybrid of the two. We also show that NSECT imaging can be used to accurately detect 3-cm lesions in backgrounds that are a significant fraction (one-quarter) of the concentration of the lesion, down to a 4-cm spacing between lesions.

Neuroimaging in specific phobia disorder: a systematic review of the literature

OBJECTIVE

Specific phobia (SP) is characterized by irrational fear associated with avoidance of specific stimuli. In recent years, neuroimaging techniques have been used in an attempt to better understand the neurobiology of anxiety disorders. The objective of this study was to perform a systematic review of articles that used neuroimaging techniques to study SP.

METHOD

A literature search was conducted through electronic databases, using the keywords: imaging, neuroimaging, PET, spectroscopy, functional magnetic resonance, structural magnetic resonance, SPECT, MRI, DTI, and tractography, combined with simple phobia and specific phobia. One-hundred fifteen articles were found, of which 38 were selected for the present review. From these, 24 used fMRI, 11 used PET, 1 used SPECT, 2 used structural MRI, and none used spectroscopy.

RESULT

The search showed that studies in this area were published recently and that the neuroanatomic substrate of SP has not yet been consolidated.

CONCLUSION

In spite of methodological differences among studies, results converge to a greater activation in the insula, anterior cingulate cortex, amygdala, and prefrontal and orbitofrontal cortex of patients exposed to phobia-related situations compared to controls. These findings support the hypotheses of the hyperactivation of a neuroanatomic structural network involved in SP.

Selective adenosine agonists and myocardial perfusion imaging

Selective adenosine receptor agonists have several advantages for use as stress agents in conjunction with myocardial perfusion imaging compared to the non selective agents such as adenosine and dipyridamole. This review will summarize the pre-clinical and clinical data on the selective adenosine agonist stress agents regadenoson (Lexiscan(®)), binodenoson (CorVue™) and apadenoson (Stedivaze™) that have been studied so far with focus on regadenoson that has the most clinical data published so far. The article will review the adenosine receptor types and properties. It will also review the various attributes of the selective adenosine agonists including their pharmacology, pharmacokinetics and pharmacodynamics, their coronary vasodilatory and hemodynamic effects, their safety and side effects, their interactions with other drugs and their use with myocardial perfusion imaging. The landmark trials of the selective adenosine agonists will be reviewed as well as their use in special patient populations undergoing stress myocardial perfusion imaging.

(111)In-octreotide scintigraphy for identification of metastatic medullary thyroid carcinoma in children and adolescents

CONTEXT

Most medullary thyroid cancers (MTC) express somatostatin receptors; therefore, (111)In-octreotide somatostatin receptor scintigraphy (SRS) may be useful in detecting sites of metastases in children with MTC.

OBJECTIVE

The aim of the study was to evaluate tumor metastases in children and adolescents with MTC using SRS in comparison to conventional imaging.

DESIGN AND SETTING

A case series was conducted as part of baseline evaluation for cancer treatment protocol at the National Institutes of Health Clinical Center.

PATIENTS

Eleven patients with a median age of 15 (range, 9-17) yr participated in the study, 10 with histologically proven, metastatic MTC due to the M918T mutation of the RET protooncogene, and one with a known RET polymorphism.

INTERVENTION

After receiving 0.086 mCi/kg (111)Indium-pentreotide, patients were examined with a single photon emission computed tomography scan 4 and 24 h after injection. Baseline conventional imaging, including computed tomography (neck, chest, abdomen, ± pelvis, adrenals), magnetic resonance imaging (neck), and bone scan, was performed on all patients.

MAIN OUTCOME MEASURES

SRS results were compared with conventional imaging.

RESULTS

Five of the 11 patients had abnormal findings on SRS. Of the 53 total target lesions present in the patients, only 24.5% were accurately identified through SRS.

CONCLUSIONS

SRS appears to be less sensitive than conventional imaging at detecting the full extent of metastatic disease in children and adolescents with hereditary MTC. SRS incompletely identified sites of tumor and failed to visualize small sites of tumor or liver and lung metastases, and it has a limited role in the evaluation of metastatic disease in pediatric MTC patients.

[Micronized purified flavonoid fraction in treatment of pelvic varicose veins]

Presented herein are the results of studying efficacy of micronized purified flavonoid fraction (MPFF) in treatment of pelvic varicose veins (PVV) using reference ray-tracing methods of study. We examined a total of 85 patients with PVV. Of these, 65 subjects were found to have isolated dilatation of pelvic venous plexuses (study group), and 20 were diagnosed as having combined dilation of gonadal veins and venous plexuses of the pelvis (control group). Besides clinical examination, the patients were subjected to ultrasonographic angioscanning (USAS) and emission computed tomography (ECT) of pelvic veins before treatment and 2, 6, 12, 24, 36 and 60 months after the beginning of phlebotrophic therapy. Based on the findings of the clinical and instrumental studies, it was determined that MPFF was most efficient in patients with isolated dilatation of uterine and parametrial veins. In this group of patients, pelvic pain and other symptoms of the disease disappeared completely and the clinical effect persisted for a long time (up to 6-9 months). In the control group, venotonic therapy had a positive effect which was less pronounced as compared to the control group, and pelvic pain reappeared in the nearest time (up to 3 weeks) after withdrawal of MPFF.

Molecular neuroimaging in Alzheimer's disease

This article reviews current amyloid positron emission tomography (PET) imaging with particular attention to Pittsburgh compound-B (PiB), the most extensively investigated and validated tracer. PiB specifically binds to fibrillar β-amyloid deposits such as those found in the cerebral cortex and striatum. PiB-PET imaging is a sensitive and specific biologic marker for underlying amyloid deposition, which is an early event on the path to dementia. Amyloid imaging in healthy controls and patients with mild cognitive impairment may detect those at high risk of future Alzheimer's disease, identifying them as candidates for early preventive measures if and when they become available.

Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy

RATIONALE

Accurate diagnosis of head and neck paragangliomas is often complicated by biochemical silence and lack of catecholamine-associated symptoms, making accurate anatomical and functional imaging techniques essential to the diagnostic process.

METHODS

Ten patients (seven SDHD, three SDHB), with a total of 26 head and neck paragangliomas, were evaluated with anatomical and functional imaging. This study compares five different functional imaging techniques [(18)F-fluorodihydroxyphenylalanine ((18)F-FDOPA) positron emission tomography (PET), (18)F-fluorodopamine ((18)F-FDA) PET/computed tomography (CT), (18)F-fluoro-2-deoxy-D-glucose ((18)F-FDG) PET/CT, (123)I-metaiodobenzylguanidine ((123)I-MIBG) scintigraphy, and (111)In-pentetreotide scintigraphy] in the localization of head and neck paragangliomas.

RESULTS

Prospectively (18)F-FDOPA PET localized 26 of 26 lesions in the 10 patients, CT/magnetic resonance imaging localized 21 of 26 lesions, (18)F-FDG PET/CT localized 20 of 26 lesions, (111)In-pentetreotide scintigraphy localized 16 of 25 lesions, (18)F-FDA PET/CT localized 12 of 26 lesions, and (123)I-MIBG scintigraphy localized eight of 26 lesions. Differences in imaging efficacy related to genetic phenotype, even in the present small sample size, included the negativity of (18)F-FDA PET/CT and (123)I-MIBG scintigraphy in patients with SDHB mutations and the accuracy of (18)F-FDG PET/CT in all patients with SDHD mutations, as compared with the accuracy of (18)F-FDG PET/CT in only one patient with an SDHB mutation.

CONCLUSION

Overall, (18)F-FDOPA PET proved to be the most efficacious functional imaging modality in the localization of SDHx-related head and neck paragangliomas and may be a potential first-line functional imaging agent for the localization of these tumors.

PET-CT scan is a valuable modality in the diagnosis of fibrolamellar hepatocellular carcinoma: a case report and a summary of recent literature

We report a case of liver cancer with features consistent with fibrolamellar hepatocellular carcinoma (FLHCC) detected by PET-CT scan. A 20-year-old female with a large liver tumor was diagnosed with 'malignant hepatic tumor' 2 years earlier and received five courses of transhepatic arterial chemoembolization (TACE) before she presented to our hospital with abdominal distension and mild pain at the right upper quadrant. Ultrasound and CT scan showed a large tumor in the right lobe of the liver. Contrast CT scan and (18)F-FDG PET-CT showed metastatic lesions in multiple organs. The imaging diagnosis was confirmed by an ultrasound-guided fine needle biopsy of the hepatic lesion which showed features of FLHCC. Immunohistochemical staining showed a marked increase in the expressions of Hepar, CD99, MIB1, proliferating cell nuclear antigen (PCNA), Fibronectin, E-cadherin and CK7. The recent knowledge on the FLHCC and the possible applications of PET-CT were discussed.

Fast-gated single-photon counting technique widens dynamic range and speeds up acquisition time in time-resolved measurements

In many time-domain single-photon measurements, wide dynamic range (more than 5 orders of magnitude) is required in short acquisition time (few seconds). We report on the results of a novel technique based on a time-gated Single-Photon Avalanche Diode (SPAD) able to increase the dynamic range of optical investigations. The optical signal is acquired only in well-defined time intervals. Very fast 200-ps gate-ON transition is used to avoid the undesired strong signal, which can saturate the detector, hide the fainter useful signal and reduce the dynamic range. In experimental measurements, we obtained a dynamic range approaching 8 decades in few minutes of acquisition.

[The progress of nuclear medicine and magnetic resonance molecular imaging of atherosclerotic vulnerable plaques]

The major goal of atherosclerotic molecular imaging is to target specific plaque-associated molecules with molecular probe that provide sensitive and specific imaging contrast and acquire molecular imaging. This method will greatly improve detection and characterization of atherosclerotic lesions, especially plaque components. The plaque components are highly associated with plaque rupture and vulnerability to rupture as well as the consequences followed plaque rupture. Thus, the knowledge about plaque composition will have tremendous clinical utility in terms of the treatment and prognosis judgment of patients with atherosclerosis.

Reconstruction of emission tomography data using origin ensembles

A new statistical reconstruction method based on origin ensembles (OE) for emission tomography (ET) is examined. Using a probability density function (pdf) derived from first principles, an ensemble expectation of numbers of detected event origins per voxel is determined. These numbers divided by sensitivities of voxels and acquisition time provide OE estimates of the voxel activities. The OE expectations are shown to be the same as expectations calculated using the complete-data space. The properties of the OE estimate are examined. It is shown that OE estimate approximates maximum likelihood (ML) estimate for conditions usually achieved in practical applications in emission tomography. Three numerical experiments with increasing complexity are used to validate theoretical findings and demonstrate similarities of ML and OE estimates. Recommendations for achieving improved accuracy and speed of OE reconstructions are provided.